Last reviewed · How we verify
Dexamethasone tapering dose
Dexamethasone tapering dose is a Small molecule drug developed by Ottawa Hospital Research Institute. It is currently FDA-approved. Also known as: dexamethasone sodium phosphate, dexamethasone acetate.
At a glance
| Generic name | Dexamethasone tapering dose |
|---|---|
| Also known as | dexamethasone sodium phosphate, dexamethasone acetate |
| Sponsor | Ottawa Hospital Research Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- LBL-2016 for Children or Adolescents in China (PHASE3)
- The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment (PHASE2)
- Post-operative Methylprednisolone Taper Course for Orthopedic Surgery (PHASE4)
- Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients (PHASE2)
- CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) (PHASE1)
- Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases (PHASE1, PHASE2)
- Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases (PHASE3)
- PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexamethasone tapering dose CI brief — competitive landscape report
- Dexamethasone tapering dose updates RSS · CI watch RSS
- Ottawa Hospital Research Institute portfolio CI
Frequently asked questions about Dexamethasone tapering dose
What is Dexamethasone tapering dose?
Dexamethasone tapering dose is a Small molecule drug developed by Ottawa Hospital Research Institute.
Who makes Dexamethasone tapering dose?
Dexamethasone tapering dose is developed and marketed by Ottawa Hospital Research Institute (see full Ottawa Hospital Research Institute pipeline at /company/ottawa-hospital-research-institute).
Is Dexamethasone tapering dose also known as anything else?
Dexamethasone tapering dose is also known as dexamethasone sodium phosphate, dexamethasone acetate.
What development phase is Dexamethasone tapering dose in?
Dexamethasone tapering dose is FDA-approved (marketed).
Related
- Manufacturer: Ottawa Hospital Research Institute — full pipeline
- Also known as: dexamethasone sodium phosphate, dexamethasone acetate
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing